Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Huperzine A

Drug Profile

Huperzine A

Alternative Names: HupA oral; Huperzine A oral; Qian-ceng-ta

Latest Information Update: 25 Sep 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chinese Academy of Sciences; Mayo Clinic
  • Developer Chinese Academy of Sciences; Neuro-Hitech
  • Class Alkaloids; Antiepileptic drugs; Neuroprotectants; Nootropics; Sesquiterpenes; Small molecules
  • Mechanism of Action Acetylcholinesterase inhibitors; Amyloid beta-protein inhibitors; Antioxidants; NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Alzheimer's disease

Most Recent Events

  • 10 Feb 2011 Discontinued - Phase-II for Alzheimer's disease in USA (PO)
  • 05 Feb 2008 Interim efficacy data from the double-blind part of a phase II trial in patients with mild-to-moderate Alzheimer's disease released by Neuro-Hitech
  • 15 Dec 2007 Neuro-Hitech completes the double-blind portion of a phase II trial in Alzheimer's disease in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top